BMO Capital analyst Evan Seigerman raised the firm’s price target on AbbVie (ABBV) to $240 from $215 and keeps an Outperform rating on the shares. AbbVie settled litigation with generic drug makers attempting to bring generic Rinvoq to market ahead of its loss of exclusivity, with the firm saying we can expect generic competition market entry in 2037, four years after its 2033 composition of matter patent expiration, the analyst tells investors in a research note. The firm noted that this outcome reads well for the name, helping to drive growth beyond current consensus expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- AbbVie’s ABBV-1088 Study: A Closer Look at Recent Developments
- AbbVie’s Rinvoq Franchise Secures Extended Exclusivity, Boosting Long-Term Prospects and Justifying Buy Rating
- ‘Really Long Runway’: AbbVie Stock (ABBV) Jumps afer Settlement on Anti-Inflammatory Drug
- Wells sees AbbVie Rinvoq settlement being worth $11-$24 per share